Published online Jun 7, 2019. doi: 10.3748/wjg.v25.i21.2581
Peer-review started: January 7, 2019
First decision: January 18, 2019
Revised: April 25, 2019
Accepted: April 29, 2019
Article in press: April 29, 2019
Published online: June 7, 2019
Processing time: 153 Days and 1.5 Hours
Gastroparesis, or symptomatic delayed gastric emptying in the absence of mechanical obstruction, is a challenging and increasingly identified syndrome. Medical options are limited and the only medication approved by the Food and Drug Administration for treatment of gastroparesis is metoclopramide, although other agents are frequently used off label. With this caveat, first-line treatments for gastroparesis include dietary modifications, antiemetics and promotility agents, although these therapies are limited by suboptimal efficacy and significant medication side effects. Treatment of patients that fail first-line treatments represents a significant therapeutic challenge. Recent advances in endoscopic techniques have led to the development of a promising novel endoscopic therapy for gastroparesis via endoscopic pyloromyotomy, also referred to as gastric per-oral endoscopic myotomy or per-oral endoscopic pyloromyotomy. The aim of this article is to review the technical aspects of the per-oral endoscopic myotomy procedure for the treatment of gastroparesis, provide an overview of the currently published literature, and outline potential next directions for the field.
Core tip: While data regarding the role of per-oral endoscopic pyloromyotomy (G-POEM) for the treatment of gastroparesis are still emerging, it is a promising technique that may significantly benefit specific gastroparesis subtypes with functional gastric outlet obstruction. More data are needed, however, to determine exactly where G-POEM falls in the armamentarium of gastroparesis treatment strategies.